Fennec Pharmaceuticals INC Form 4 insider transactions

Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares on April 4, 2025, at a price of $5.25 per share, according to a Form 4 filing.

Christiana Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals, was granted 10,000 restricted share units on March 28, 2025, according to a Form 4/A filing.

Pierre Sayad, Chief Medical Officer of Fennec Pharmaceuticals, was granted 10,000 restricted share units on March 28, 2025, according to a Form 4 filing.

Terry Evans, Chief Commercial Officer of Fennec Pharmaceuticals, reports the acquisition of 10,000 restricted share units.

CEO Jeffrey Hackman receives 75,000 restricted share units and options for 50,000 shares of Fennec Pharmaceuticals stock.

Robert Andrade, CFO of Fennec Pharmaceuticals, was granted stock options and restricted share units on March 28, 2025, according to a Form 4 filing.

CEO Jeffrey Hackman of Fennec Pharmaceuticals was granted stock options and restricted share units on March 28, 2025, according to a Form 4 filing.

Terry Evans, Chief Commercial Officer of Fennec Pharmaceuticals, received 10,000 restricted share units under the company's 2020 Equity Incentive Plan.

Christiana Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals, was granted 10,000 restricted share units on March 28, 2025, according to a Form 4 filing.

Director Rosty Raykov reports acquiring and disposing of Fennec Pharmaceuticals shares on March 31, 2025, resulting from the release of restriction from shares awarded on March 31, 2023.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on March 31, 2025, resulting in a decrease in his beneficially owned securities.

Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares at $6.79 per share on March 5, 2025, according to a Form 4 filing.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on February 28, 2025, resulting in a total beneficial ownership of 131,549 shares.

Director Rosty Raykov reports acquiring and disposing of Fennec Pharmaceuticals common shares on February 28, 2025, resulting from the release of restrictions on previously awarded shares.

Director Chris A. Rallis of Fennec Pharmaceuticals reports exercising options and selling shares to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals sold 10,000 common shares on February 5, 2025, at a price of $6.66 per share, according to a Form 4 filing with the SEC.

A Fennec Pharmaceuticals director, Rosty Raykov, acquired 2,431 common shares through the vesting of restricted stock.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,042 common shares through the vesting of restricted stock.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of common shares on January 6, 2025, according to a Form 4 filing.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,042 common shares through the vesting of restricted stock.

A Fennec Pharmaceuticals director, Rosty Raykov, acquired 2,431 common shares due to the release of restrictions on previously awarded shares.

Director Rosty Raykov acquired 25,000 common shares of Fennec Pharmaceuticals through option exercise at a price of $2.69 on December 20, 2024.

A Fennec Pharmaceuticals director, Rosty Raykov, sold 796 common shares at $6.04 per share on December 5, 2024, under a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals reported acquiring 2,431 shares through the release of restricted stock and selling 1,635 shares under a pre-arranged 10b5-1 plan.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,042 common shares through the vesting of restricted stock.

A Fennec Pharmaceuticals director, Chris A Rallis, exercised options to acquire 10,000 shares and sold 6,409 shares to cover tax obligations.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, exercised stock options to acquire 15,816 common shares at $2.45 per share.

Christiana Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals, was granted 150,000 incentive stock options on November 13, 2024.

Fennec Pharmaceuticals' Chief Commercial Officer, Terry L. Evans, was granted incentive stock options for 150,000 common shares on November 13, 2024.

Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sayad, was granted 150,000 stock options on November 13, 2024, under the company's 2020 Equity Incentive Plan.